What is Palvella Therapeutics's debt issuance costs?

Palvella Therapeutics (PVLA) reported debt issuance costs of $14.25M in Q1 2026.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

Palvella Therapeutics PVLA Debt Issuance Costs

Debt Issuance Costs at other companies

Viridian Therapeutics, Inc.VRDN

$119.5K—

Ligand PharmaceuticalsLGND

$50K-29.6%

Arrowhead ResearchARWR

$18.72M—

BioCryst PharmaceuticalsBCRX

$4.95M—

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

See full

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Cash flow

See full

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

See full

Market cap$1.86B+468%

Profitability

See full

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

See full

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfFinancingCosts.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Palvella Therapeutics's debt issuance costs?: Palvella Therapeutics (PVLA) reported debt issuance costs of $14.25M in Q1 2026.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.